News

VANCOUVER, BRITISH COLUMBIA, September 7, 2021- Pascal Biosciences Inc. (“Pascal”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB-FF), announced today the appointment of Rob Gietl as Chief Executive Officer and President, and he will also have a position on the Board of Directors. Mr. Gietl…

VANCOUVER, BRITISH COLUMBIA, June 16, 2021- Pascal Biosciences Inc. (“Pascal”) (TSXV:PAS) (OTC:PSCBF) (FSE: 6PB), announced today the appointment of Hardy Forzley as Chief Financial Officer. Mr. Forzley has used his professional expertise as a Certified Public Accountant with some 30 years…

VANCOUVER, BRITISH COLUMBIA, June 8, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF), has been awarded a grant of US$343,750 from the National Cancer Institute of the US National Institutes of Health (NIH).  This two-year award will fund…

VANCOUVER, BRITISH COLUMBIA, June 2, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:PSCBF, previously BIMUF), has today received a new Over The Counter (OTC) trading symbol following acceptance of Form 211 by the US Financial Industry Regulatory Authority…

VANCOUVER, BRITISH COLUMBIA, March 22, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer, cannabinoids, and Covid-19 is announcing several management changes following its recent capital raise. First, Chairman of the Board…

VANCOUVER, BRITISH COLUMBIA, March 18, 2021- Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV:PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer, cannabinoids, and Covid-19 is pleased to announce the closing of the second tranche of the non-brokered private placement…

VANCOUVER, BRITISH COLUMBIA, January 22, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer drug discovery and development, has amended the terms of the non-brokered private placement (the “Private Placement”)…

VANCOUVER, BRITISH COLUMBIA, January 21, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today. Dr. Patrick Gray, CEO of Pascal Biosciences, will present advancements of Pascal’s…

VANCOUVER, BRITISH COLUMBIA, January 19, 2021 - Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV: PAS) (OTC:BIMUF), a biotechnology company that specializes in cancer drug discovery and development, has amended the terms of the non-brokered private placement (the “Private Placement”)…

SEATTLE, WASHINGTON and VANCOUVER, BRITISH COLUMBIA, December 8, 2020 - Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) and SōRSE Technology Corporation (“SōRSE”) have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the…